ClinicalTrials.gg
CompletedNCT07652697Updated Jun 17, 2026

ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants

A Phase 1 interventional study of ABX-002 in Healthy, sponsored by Autobahn Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Autobahn Therapeutics, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.
  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2025, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to assess the bioequivalence (BE) between the liquid formulation and the new solid formulation of ABX-002 under fasting conditions and to evaluate the effect of food on the pharmacokinetics (PK) of the new solid formulation of ABX-002.This study design is consistent with FDA guidelines for the assessment of BE.

This was an open label, randomized, single dose, three-way crossover BE and food-effect study. Therefore, the total number of participants in this study was 18.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
  • Bioequivalence
  • Elunetirom
03

In context

Lead sponsor

Autobahn Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
  • ≥ 18.0 and ≤ 32.0 kg/m2 and minimum weight of 50 kg at the screening visit
  • Medically healthy, as deemed by the PI or designee, with no medical history, or clinically significant abnormalities in physical examination, clinical laboratory profiles, and vital signs
  • Capable of providing written , able to understand the nature of the trial and, in the opinion of the PI or designee, able to follow all protocol requirements including the schedule of assessments

Exclusion criteria

Exclusion Criteria:

  • Mentally or legally incapacitated or had significant emotional problems at the time of the screening visit or expected during the conduct of the study
  • History of any illness that, in the opinion of the PI or designee, might have confounded the results of the study or posed an additional risk to the participant
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
  • History or presence of or idiosyncratic reaction to the study drug or related compounds
  • History of thyroid disease
  • History or presence of cataract, glaucoma, severe ocular trauma, inflammatory eye disease, or prior ophthalmic surgical procedures or laser surgery in either eye.
  • Clinically significant abnormalities on 12-lead at the screening visit
  • Positive urine drug or alcohol results at the screening visit or check-in
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Sequence ABC

    Sequence ABC

    Drug: ABX-002

  • Experimental
    Sequence BCA

    Sequence BCA

    Drug: ABX-002

  • Experimental
    Sequence CAB

    Sequence CAB

    Drug: ABX-002

  • Experimental
    Sequence ACB

    Sequence ACB

    Drug: ABX-002

  • Experimental
    Sequence BAC

    Sequence BAC

    Drug: ABX-002

  • Experimental
    Sequence CBA

    Sequence CBA

    Drug: ABX-002

Interventions

  • ABX-002 was supplied as a solution and solid dose form.

06

What researchers measure

Primary outcomes

  1. Evaluate the bioequivalence between ABX-002 liquid formulation and ABX-002 solid formulation in healthy adult participants.

    Change in Area Under the Curve from time zero to the last quantifiable concentration for ABX-002 and LL-340001

    Time frame: 8 weeks

  2. Evaluate the bioequivalence between ABX-002 liquid formulation and ABX-002 solid formulation

    Change in Area Under the Curve from time zero to infinity for ABX-002 and LL-340001

    Time frame: 8 weeks

  3. Evaluate the bioequivalence between ABX-002 liquid formulation and ABX-002 solid formulation

    Change in Peak Plasma Concentration for ABX-002 and LL-340001

    Time frame: 8 weeks

Secondary outcomes

  1. Evaluate the effect of a high-fat meal on the PK of ABX-002 solid formulation in healthy adult participants

    Change in Change in Area Under the Curve from time zero to the last quantifiable concentration for ABX-002 and LL-340001

    Time frame: 8 weeks

  2. Evaluate the effect of a high-fat meal on the PK of ABX-002 solid formulation in healthy adult participants

    Change in Area Under the Curve from time zero to infinity for ABX-002 and LL-340001

    Time frame: 8 weeks

  3. Evaluate the effect of a high-fat meal on the PK of ABX-002 solid formulation in healthy adult participants

    Change in Peak Plasma Concentration for ABX-002 and LL-340001

    Time frame: 8 weeks

  4. Evaluate the safety and tolerability of 3 total doses of ABX-002 in healthy adult participants.

    Incidence and severity of treatment-emergent adverse events to ABX-002 will be measured

    Time frame: 8 weeks

07

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Feb 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 17, 2026
StartActual
Jan 2, 2025
Primary completionActual
Feb 17, 2025
CompletionActual
Feb 17, 2025
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07652697
Lead sponsor
Autobahn Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jan 2, 2025
Primary completion
Feb 17, 2025
Completion
Feb 17, 2025
Last update
Jun 17, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elunetirom

Start the discussion